Skip to main content

Teva Pharmaceutical Industries



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1.4%. By the end of trading, Teva Pharmaceutical Industries fell 27 cents (-0.7%) to $39.04 on average volume. Throughout the day, 5.5 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.8 million shares. The stock ranged in price between $38.99-$39.44 after having opened the day at $39.34 as compared to the previous trading day's close of $39.31. Other company's within the Drugs industry that declined today were:

Omeros Corporation



), down 20%,

Osiris Therapeutics



), down 17.4%,




), down 11.9%, and

TheStreet Recommends




), down 10.6%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.6 billion and is part of the

health care

sector. The company has a P/E ratio of 12.9, above the average drugs industry P/E ratio of 12.3 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.6% year to date as of the close of trading on Tuesday. Currently there are 22 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself.

On the positive front,

Aoxing Pharmaceutical Company



), up 34.9%,

Arena Pharmaceuticals



), up 28.7%,

Orexigen Therapeutics



), up 20.3%, and

Arrowhead Research Corporation



), up 19%, were all gainers within the drugs industry with

Abbott Laboratories



) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech